This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, J. Articles by Freeman, M. R. Search for Related Content PubMed PubMed Citation Articles by Kim, J. Articles by Freeman, M. R.

Activation of the Erk Mitogen-activated Protein Kinase Pathway Stimulates Neuroendocrine Differentiation in LNCaP Cells Independently of Cell Cycle Withdrawal and STAT3 Phosphorylation¹

The Urologic Laboratory, Department of Urology, Children’s Hospital, and the Department of Surgery, Harvard Medical School, Boston, Massachusetts 02115

Neuroendocrine (NE) differentiation in prostate cancer (PCa) has been found in some studies to correlate with unfavorable clinical outcome. The mechanisms by which PCa acquires NE properties are poorly understood. In this study, we demonstrate that heparin-binding epidermal growth factor-like growth factor (HB-EGF), a prostate smooth muscle-derived mitogen and survival factor, can evoke NE differentiation in LNCaP human PCa cells. HB-EGF induction of NE differentiation was mediated by a mitogen-activated protein kinase (MAPK) kinase-dependent mechanism, and this process was blocked by p38 MAPK signaling. NE differentiation induced by HB-EGF occurred independently of STAT3 phosphorylation and coincided with continued cell cycle transit. These findings suggest that endogenous stroma-derived factors, acting through MAPK signaling pathways, may play a significant role in the acquisition of NE properties by PCa cells. They also demonstrate that withdrawal from the cell cycle is not a prerequisite for expression of NE characteristics by PCa.

This article has been cited by other articles:

				W. J. Brackenbury, M. B.A. Djamgoz, and L. L. Isom An Emerging Role for Voltage-Gated Na+ Channels in Cellular Migration: Regulation of Central Nervous System Development and Potentiation of Invasive Cancers Neuroscientist, December 1, 2008; 14(6): 571 - 583. [Abstract] [PDF]

				T.-C. Yuan, S. Veeramani, and M.-F. Lin Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells Endocr. Relat. Cancer, September 1, 2007; 14(3): 531 - 547. [Abstract] [Full Text] [PDF]

				C. Wu and J. Huang Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer J. Biol. Chem., February 9, 2007; 282(6): 3571 - 3583. [Abstract] [Full Text] [PDF]

				T.-C. Yuan, S. Veeramani, F.-F. Lin, D. Kondrikou, S. Zelivianski, T. Igawa, D. Karan, S. K. Batra, and M.-F. Lin Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 151 - 167. [Abstract] [Full Text] [PDF]

				S Humez, M Monet, G Legrand, G Lepage, P Delcourt, and N Prevarskaya Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr. Relat. Cancer, March 1, 2006; 13(1): 181 - 195. [Abstract] [Full Text] [PDF]

				K.-T. Chang, C.-Y. F. Huang, C.-M. Tsai, C.-H. Chiu, and Y.-Y. Lok Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L438 - L445. [Abstract] [Full Text] [PDF]

				B. Cinar, A. De Benedetti, and M. R. Freeman Post-Transcriptional Regulation of the Androgen Receptor by Mammalian Target of Rapamycin Cancer Res., April 1, 2005; 65(7): 2547 - 2553. [Abstract] [Full Text] [PDF]

				P. M Ghosh, S. N Malik, R. G Bedolla, Y. Wang, M. Mikhailova, T. J Prihoda, D. A Troyer, and J. I Kreisberg Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocr. Relat. Cancer, March 1, 2005; 12(1): 119 - 134. [Abstract] [Full Text] [PDF]

				D. J. George, S. Halabi, T. F. Shepard, B. Sanford, N. J. Vogelzang, E. J. Small, and P. W. Kantoff The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 Clin. Cancer Res., March 1, 2005; 11(5): 1815 - 1820. [Abstract] [Full Text] [PDF]

				J. I. Kreisberg, S. N. Malik, T. J. Prihoda, R. G. Bedolla, D. A. Troyer, S. Kreisberg, and P. M. Ghosh Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer Cancer Res., August 1, 2004; 64(15): 5232 - 5236. [Abstract] [Full Text] [PDF]

				P. P. Ongusaha, J. C. Kwak, A. J. Zwible, S. Macip, S. Higashiyama, N. Taniguchi, L. Fang, and S. W. Lee HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis Cancer Res., August 1, 2004; 64(15): 5283 - 5290. [Abstract] [Full Text] [PDF]

				J. P. Carson, N. Zhang, G. M. Frampton, N. P. Gerry, M. E. Lenburg, and M. F. Christman Pharmacogenomic Identification of Targets for Adjuvant Therapy with the Topoisomerase Poison Camptothecin Cancer Res., March 15, 2004; 64(6): 2096 - 2104. [Abstract] [Full Text] [PDF]

				J. Kim, R. M. Adam, K. R. Solomon, and M. R. Freeman Involvement of Cholesterol-Rich Lipid Rafts in Interleukin-6-Induced Neuroendocrine Differentiation of LNCaP Prostate Cancer Cells Endocrinology, February 1, 2004; 145(2): 613 - 619. [Abstract] [Full Text] [PDF]

				N. N. Gushwa, D. Hayashi, A. Kemper, B. Abram, J. E. Taylor, J. Upton, C. F. Tay, S. Fiedler, S. Pullen, L. P. Miller, et al. Thermotolerant Guard Cell Protoplasts of Tree Tobacco Do Not Require Exogenous Hormones to Survive in Culture and Are Blocked from Reentering the Cell Cycle at the G1-to-S Transition Plant Physiology, August 1, 2003; 132(4): 1925 - 1940. [Abstract] [Full Text] [PDF]

				R. M. Adam, J. Kim, J. Lin, A. Orsola, L. Zhuang, D. C. Rice, and M. R. Freeman* Heparin-Binding Epidermal Growth Factor-Like Growth Factor Stimulates Androgen-Independent Prostate Tumor Growth and Antagonizes Androgen Receptor Function Endocrinology, December 1, 2002; 143(12): 4599 - 4608. [Abstract] [Full Text] [PDF]